Molbio Diagnostics Ltd. IPO Details
Molbio Diagnostics was incorporated on October 20, 2000. The company develops innovative point-of-care diagnostics through its patented ‘Truenat’ PCR platform, enabling rapid testing for 30+ diseases across 100+ countries. It also offers radiology, digital pathology, and breast health solutions while building a pipeline of new products
| Bidding Dates |
|---|
| 10 Aug 2026 - 12 Aug 2026 |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹13,824 | 1 | 13 | 18 | 11.6 M | ₹768 - ₹807 | 43.01 % | ₹8942.8 M - ₹9397.0 M | RHP DOC |
Molbio Diagnostics issue details
Molbio Diagnostics has 11.6 M shares on offer
Molbio Diagnostics IPO offer price is in the range ₹768 - ₹807
Molbio Diagnostics IPO minimum Investment is ₹13824
Molbio Diagnostics IPO issue size is ₹ 8942.8 M - ₹ 9397.0 M
Molbio Diagnostics has a minimum lot size of 18 Shares per application
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
Molbio Diagnostics IMPORTANT IPO DATES
| Issue Open Date | 10 Aug 2026 |
| Issue close Date | 12 Aug 2026 |
| Allotment Date | 13 Aug 2026 |
| Refund Date | 14 Aug 2026 |
| Demat Account Credit Date | 14 Aug 2026 |
| Listing Date | 17 Aug 2026 |
| Listing on Exchange(s) | NSE and BSE |
Molbio Diagnostics IPO subscription opens on 10 Aug 2026, and closes on 12 Aug 2026
IPO allotment for Molbio Diagnostics is expected to be finalized on Thursday, 13 Aug 2026
IPO listing for Molbio Diagnostics will be on NSE and BSE on Monday, 17 Aug 2026
Molbio Diagnostics NUMBER OF SHARES ON OFFER
Molbio Diagnostics FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| FY26 | 1,445.7 | 164.1 | 50.4 | 0.8 | 22.6% |
| FY25 | 1,020.4 | 138.6 | 287.1 | 232.5 | 25.0% |
| FY24 | 836.6 | 83.5 | 9.6 | -6.5 | 22.0% |
Molbio Diagnostics Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molbio Diagnostics Ltd. | 807 | 9299.7 | 55.8 | 3.8 | 6.4 | 14.2 | 7.8 | 1455.2 | 41.6 | 166.6 | 14.8 | 14.5 | 14.8 |
| Dr. Lal Pathlabs Ltd. | 1931.6 | 32421.7 | 59.8 | 10.7 | 11.2 | 20.1 | 16 | 2864.2 | 12.1 | 504.8 | 3.6 | 32.3 | 5.6 |
| Inventurus Knowledge Solutions Ltd. | 1737.7 | 29814.3 | 39 | 1 | 8.9 | 25.8 | 16.9 | 3211 | 18.8 | 721.6 | 48.4 | 44.5 | 40.9 |
| Vijaya Diagnostic Centre Ltd. | 1351.1 | 13916 | 74.2 | 3 | 16.2 | 18.1 | 11.5 | 835 | 19.3 | 173 | 20.9 | 18.2 | 24.9 |
| Indegene Ltd. | 554.4 | 13357.5 | 33.3 | -4.2 | 3.5 | 12.8 | 8.7 | 3582.5 | 21.6 | 401.1 | -1.4 | 16.6 | -7.9 |
| Metropolis Healthcare Ltd. | 563.2 | 11680.1 | 57.9 | 1.8 | 6.8 | 12.6 | 8.9 | 1671.4 | 24.1 | 190 | 31.1 | 9.7 | 32.6 |
Molbio Diagnostics INFORMATION ON IPO ISSUE
About Molbio Diagnostics
Molbio Diagnostics was incorporated on October 20, 2000. The company develops innovative point-of-care diagnostics through its patented ‘Truenat’ PCR platform, enabling rapid testing for 30+ diseases across 100+ countries. It also offers radiology, digital pathology, and breast health solutions while building a pipeline of new products
Object of the Issue
- Funding capital expenditure towards the setting up of infrastructure for the research and development facility, Centre of Excellence and connected office space
- Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for the Goa & Visakhapatnam Units
- General corporate purposes
Molbio Diagnostics - PROMOTERS
| Name |
|---|
| Sriram Natarajan |
| Chandrasekhar Bhaskaran Nair |
| Sangeetha Sriram |
| Shiva Sriram |
| Sowmya Sriram |
| Exxora Trading LLP |
Molbio Diagnostics - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Sriram Natarajan | Executive Director & Chief Executive Officer |
| Chandrasekhar Bhaskaran Nair | Executive Director & Chief Technology Officer |
| Sangeetha Sriram | Executive Director & Director Operations |
| Arun Kumar Jha | Independent Director |
| Balram Bhargava | Independent Director |
| Nupur Garg | Independent Director |
Molbio Diagnostics Book Running Lead Manager
Kotak Mahindra Capital Company Limited
molbio.ipo@kotak.com
IIFL Capital Services Limited
molbio.ipo@iiflcap.com
Jefferies India Private Limited
Molbio.IPO@jefferies.com
Motilal Oswal Investment Advisors Limited
molbio.ipo@motilaloswal.com
Molbio Diagnostics Registrar to the Offer
KFin Technologies Limited
molbio.ipo@kfintech.com
Molbio Diagnostics Strengths
Innovative and R&D focused
The company has strong in-house R&D through its subsidiary Bigtec, with a proven record of developing innovative POC diagnostic platforms. Its 13+ years of research led to ICMR-certified solutions, including one of the earliest POC PCR platforms for influenza and swine flu diagnosis
Truenat platform
The company has developed and commercialised ‘Truenat,’ a portable POC molecular diagnostics platform using PCR technology. It includes the Trueprep device for automated sample preparation, the Truelab analyser for real-time PCR, and ready-to-use Truenat test kits for disease-specific diagnostics
Scalable business model
The company’s ‘Truenat’ platform is a closed system of Trueprep and Truelab devices that work exclusively with its disease-specific test kits, ensuring recurring demand. With WHO endorsement for TB diagnosis and high entry barriers backed by 13 years of R&D, the platform enables testing for multiple diseases on the same device, enhancing value for healthcare providers
Molbio Diagnostics Risks
Complex & uncertain sales cycle
The company’s sales cycle is complex and variable, involving multiple stakeholders such as clinicians, pathologists, and laboratories. Dependence on clinician prescriptions, government orders, and lengthy approval processes often leads to delays and fluctuations in demand, making accurate sales forecasting challenging
Inventory risks
The company’s inability to accurately forecast demand or manage inventory can impact operations and finances. Unpredictable factors like disease outbreaks or sudden large orders may cause excess stock or shortages, leading to potential business loss
Product liability & regulatory risks
Product liability claims, regulatory actions, or penalties for failing contractual obligations may harm the company’s business, finances, and reputation. Such claims can be costly, time-consuming, and may result in substantial damages or loss of brand credibility
IPO FAQs
This IPO consists of an offer for sale of up to Rs 739.7 crore, of 9,166,000 shares. It also consists of a fresh issue of Rs 200.0 crore.
The promoters of the company are Sriram Natarajan, Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Exxora Trading LLP.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 768.0 - 807.0.
The IPO application opens on Aug 10, 2026 and closes on Aug 12, 2026.
The minimum lot size for the IPO is 18. The maximum lot size for the IPO is 234.
For all category investors, the minimum application amount for this IPO is Rs. 13,824.0, the maximum value for this IPO is Rs 188,838.0.
This IPO will be allotted on Aug 13, 2026.
The refund will be credited to your account on Aug 14, 2026.
The allotted shares will be credited to your demat on Aug 14, 2026.
Molbio Diagnostics Ltd.’s shares will list on the stock exchanges on Aug 17, 2026.